[A21-22] Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V

Last updated 17.05.2021

Project no.:

Commission awarded on 12.02.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Immune system and infections


Adult and adolescent patients aged 12 years and above with influenza exposure

Result of dossier assessment:

Affected people without risk of influenza-related complications: indication of considerable added benefit.

Affected people with risk of influenza-related complications: added benefit not proven.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form